Afinitor
Advance Directives, Steroid therapy, Carcinoid Tumor + 11 more
Treatment
22 FDA approvals
0 Active Studies for Afinitor
Treatment for
Advance Directives
What is Afinitor
Everolimus
The Generic name of this drug
Treatment Summary
Everolimus is a medication related to Rapamycin that prevents organ rejection after transplantation. It works by inhibiting the mTORC1 protein, a protein that helps control cell growth. Unlike other mTOR inhibitors, it does not affect the mTORC2 protein.
Afinitor
is the brand name
Afinitor Overview & Background
Brand Name
Generic Name
First FDA Approval
How many FDA approvals?
Afinitor
Everolimus
2009
59
Approved as Treatment by the FDA
Everolimus, also known as Afinitor, is approved by the FDA for 22 uses including Kidney Transplant Rejection and unresectable gastrointestinal origin Progressive Neuroendocrine Tumors .
Kidney Transplant Rejection
Used to treat Kidney Transplant Rejection in combination with Basiliximab
unresectable gastrointestinal origin Progressive Neuroendocrine Tumors
Subependymal giant cell astrocytoma, tuberous sclerosis complex
locally advanced lung origin Progressive Neuroendocrine Tumors
Tuberous Sclerosis
Neuroendocrine Tumors
Tuberous Sclerosis
Lung
metastatic lung origin Progressive Neuroendocrine Tumors
pancreatic origin Progressive Neuroendocrine Tumors
Liver Transplant Rejection
Used to treat Liver Transplant Rejection in combination with Tacrolimus
metastatic gastrointestinal origin Progressive Neuroendocrine Tumors
unresectable lung origin Progressive Neuroendocrine Tumors
locally advanced gastrointestinal origin Progressive Neuroendocrine Tumors
Advance Directives
Used to treat refractory, advanced Breast cancer in combination with Exemestane
Renal angiomyolipoma, tuberous sclerosis complex
refractory Advanced Renal Cell Carcinoma
Neuroendocrine Tumors
Neoplasm Metastasis
Neuroendocrine Tumors
Steroid therapy
Used to treat Steroid therapy in combination with Tacrolimus
Neuroendocrine Tumors
Effectiveness
How Afinitor works in the body
Everolimus is a drug that works by blocking the mTOR protein, which helps control cell growth. By blocking mTOR, everolimus stops cells from transitioning from G1 to S phase, which halts cell growth and causes cell death. This drug also reduces the expression of a protein that helps produce vascular endothelial growth factor. Inhibiting mTOR has the additional effect of reducing cell proliferation, angiogenesis, and glucose uptake.
When to interrupt dosage
The prescribed dose of Afinitor is contingent upon the diagnosed affliction, such as metastatic lung source Progressive Neuroendocrine Tumors, Heart and Advance Directives. Dosage fluctuates as per the technique of administering (e.g. Tablet or Oral) expressed in the table beneath.
Condition
Dosage
Administration
Advance Directives
2.0 mg, , 3.0 mg, 5.0 mg, 10.0 mg, 2.5 mg, 0.25 mg, 0.5 mg, 0.75 mg, 7.5 mg, 1.0 mg
Tablet, for suspension, Oral, Tablet, for suspension - Oral, , Tablet - Oral, Tablet
Steroid therapy
2.0 mg, , 3.0 mg, 5.0 mg, 10.0 mg, 2.5 mg, 0.25 mg, 0.5 mg, 0.75 mg, 7.5 mg, 1.0 mg
Tablet, for suspension, Oral, Tablet, for suspension - Oral, , Tablet - Oral, Tablet
Carcinoid Tumor
2.0 mg, , 3.0 mg, 5.0 mg, 10.0 mg, 2.5 mg, 0.25 mg, 0.5 mg, 0.75 mg, 7.5 mg, 1.0 mg
Tablet, for suspension, Oral, Tablet, for suspension - Oral, , Tablet - Oral, Tablet
Tuberous Sclerosis
2.0 mg, , 3.0 mg, 5.0 mg, 10.0 mg, 2.5 mg, 0.25 mg, 0.5 mg, 0.75 mg, 7.5 mg, 1.0 mg
Tablet, for suspension, Oral, Tablet, for suspension - Oral, , Tablet - Oral, Tablet
Tuberous Sclerosis
2.0 mg, , 3.0 mg, 5.0 mg, 10.0 mg, 2.5 mg, 0.25 mg, 0.5 mg, 0.75 mg, 7.5 mg, 1.0 mg
Tablet, for suspension, Oral, Tablet, for suspension - Oral, , Tablet - Oral, Tablet
Waldenstrom Macroglobulinemia
2.0 mg, , 3.0 mg, 5.0 mg, 10.0 mg, 2.5 mg, 0.25 mg, 0.5 mg, 0.75 mg, 7.5 mg, 1.0 mg
Tablet, for suspension, Oral, Tablet, for suspension - Oral, , Tablet - Oral, Tablet
refractory Advanced Renal Cell Carcinoma
2.0 mg, , 3.0 mg, 5.0 mg, 10.0 mg, 2.5 mg, 0.25 mg, 0.5 mg, 0.75 mg, 7.5 mg, 1.0 mg
Tablet, for suspension, Oral, Tablet, for suspension - Oral, , Tablet - Oral, Tablet
Neoplasm Metastasis
2.0 mg, , 3.0 mg, 5.0 mg, 10.0 mg, 2.5 mg, 0.25 mg, 0.5 mg, 0.75 mg, 7.5 mg, 1.0 mg
Tablet, for suspension, Oral, Tablet, for suspension - Oral, , Tablet - Oral, Tablet
Neuroendocrine Tumors
2.0 mg, , 3.0 mg, 5.0 mg, 10.0 mg, 2.5 mg, 0.25 mg, 0.5 mg, 0.75 mg, 7.5 mg, 1.0 mg
Tablet, for suspension, Oral, Tablet, for suspension - Oral, , Tablet - Oral, Tablet
Neuroendocrine Tumors
2.0 mg, , 3.0 mg, 5.0 mg, 10.0 mg, 2.5 mg, 0.25 mg, 0.5 mg, 0.75 mg, 7.5 mg, 1.0 mg
Tablet, for suspension, Oral, Tablet, for suspension - Oral, , Tablet - Oral, Tablet
pancreatic origin Progressive Neuroendocrine Tumors
2.0 mg, , 3.0 mg, 5.0 mg, 10.0 mg, 2.5 mg, 0.25 mg, 0.5 mg, 0.75 mg, 7.5 mg, 1.0 mg
Tablet, for suspension, Oral, Tablet, for suspension - Oral, , Tablet - Oral, Tablet
Neuroendocrine Tumors
2.0 mg, , 3.0 mg, 5.0 mg, 10.0 mg, 2.5 mg, 0.25 mg, 0.5 mg, 0.75 mg, 7.5 mg, 1.0 mg
Tablet, for suspension, Oral, Tablet, for suspension - Oral, , Tablet - Oral, Tablet
Lung
2.0 mg, , 3.0 mg, 5.0 mg, 10.0 mg, 2.5 mg, 0.25 mg, 0.5 mg, 0.75 mg, 7.5 mg, 1.0 mg
Tablet, for suspension, Oral, Tablet, for suspension - Oral, , Tablet - Oral, Tablet
Neuroendocrine Tumors
2.0 mg, , 3.0 mg, 5.0 mg, 10.0 mg, 2.5 mg, 0.25 mg, 0.5 mg, 0.75 mg, 7.5 mg, 1.0 mg
Tablet, for suspension, Oral, Tablet, for suspension - Oral, , Tablet - Oral, Tablet
Warnings
There are 20 known major drug interactions with Afinitor.
Common Afinitor Drug Interactions
Drug Name
Risk Level
Description
2-Methoxyethanol
Major
The risk or severity of adverse effects can be increased when Everolimus is combined with 2-Methoxyethanol.
9-(N-methyl-L-isoleucine)-cyclosporin A
Major
The risk or severity of adverse effects can be increased when Everolimus is combined with 9-(N-methyl-L-isoleucine)-cyclosporin A.
Abemaciclib
Major
The serum concentration of Abemaciclib can be increased when it is combined with Everolimus.
Abetimus
Major
The risk or severity of adverse effects can be increased when Everolimus is combined with Abetimus.
Acteoside
Major
The risk or severity of adverse effects can be increased when Everolimus is combined with Acteoside.
Afinitor Toxicity & Overdose Risk
The amount of the drug needed to inhibit a certain biological process is 0.63 nM.
Afinitor Novel Uses: Which Conditions Have a Clinical Trial Featuring Afinitor?
16 active trials are investigating the potential of Afinitor in alleviating locally advanced lung origin Progressive Neuroendocrine Tumors, advanced Carcinoid tumor and Heart related afflictions.
Condition
Clinical Trials
Trial Phases
pancreatic origin Progressive Neuroendocrine Tumors
0 Actively Recruiting
Steroid therapy
0 Actively Recruiting
Carcinoid Tumor
0 Actively Recruiting
Tuberous Sclerosis
0 Actively Recruiting
Advance Directives
0 Actively Recruiting
refractory Advanced Renal Cell Carcinoma
0 Actively Recruiting
Tuberous Sclerosis
0 Actively Recruiting
Neuroendocrine Tumors
0 Actively Recruiting
Neuroendocrine Tumors
0 Actively Recruiting
Neuroendocrine Tumors
0 Actively Recruiting
Neuroendocrine Tumors
0 Actively Recruiting
Waldenstrom Macroglobulinemia
0 Actively Recruiting
Neoplasm Metastasis
0 Actively Recruiting
Lung
0 Actively Recruiting
Afinitor Reviews: What are patients saying about Afinitor?
5
Patient Review
1/30/2013
Afinitor for Hormone Receptor Positive Postmenopausal Advanced Breast Cancer
5
Patient Review
12/3/2016
Afinitor for Cancer of Pancreas Islet Cells
5
Patient Review
11/6/2012
Afinitor for Hormone Receptor Positive Postmenopausal Advanced Breast Cancer
5
Patient Review
8/17/2013
Afinitor for Hormone Receptor Positive Postmenopausal Advanced Breast Cancer
4.3
Patient Review
10/17/2014
Afinitor for Hormone Receptor Positive Postmenopausal Advanced Breast Cancer
4
Patient Review
12/9/2012
Afinitor for Cancer Involving the Kidney Cells
4
Patient Review
5/2/2011
Afinitor for Cancer Involving the Kidney Cells
3.7
Patient Review
11/13/2011
Afinitor for Subependymal Giant Cell Astrocytoma associated with Tuberous Sclerosis
3.7
Patient Review
8/24/2010
Afinitor for Cancer Involving the Kidney Cells
3.3
Patient Review
9/24/2014
Afinitor for Cancer Involving the Kidney Cells
3.3
Patient Review
11/24/2015
Afinitor for Hormone Receptor Positive Postmenopausal Advanced Breast Cancer
2.3
Patient Review
1/7/2017
Afinitor for Hormone Receptor Positive Postmenopausal Advanced Breast Cancer
1.7
Patient Review
3/26/2015
Afinitor for Renal Angiomyolipoma with Tuberous Sclerosis Complex
1
Patient Review
10/7/2011
Afinitor for Cancer Involving the Kidney Cells
1
Patient Review
7/31/2010
Afinitor for Cancer Involving the Kidney Cells
1
Patient Review
3/18/2014
Afinitor for Hormone Receptor Positive Postmenopausal Advanced Breast Cancer
Patient Q&A Section about afinitor
These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
What is the drug Afinitor used for?
"Everolimus is a targeted cancer drug that blocks cancer growth. It is also known by its brand name Afinitor. People with advanced breast cancer that is hormone receptor positive might take everolimus."
Answered by AI
What are the side effects of Afinitor?
"The following are symptoms of an infection: rash, feeling weak or tired, diarrhea, swelling of arms, hands, feet, ankles, face, or other parts of the body, stomach (abdominal) pain, nausea, and fever."
Answered by AI
Can afinitor shrink tumors?
"Afinitor is the only drug that has been approved by the U.S. FDA that has been shown to prolong patient survival by a few months."
Answered by AI
Is afinitor a good drug?
"Afinitor has a mixed reputation for the treatment of Breast cancer, with an average rating of 4.6 out of 10 from a total of 10 reviewers. 40% reported a positive experience, while the other 60% had a negative experience."
Answered by AI
What is the drug AFINITOR used for?
"Everolimus is a targeted cancer drug that inhibits cancer growth. It is also known by its brand name, Afinitor. You may be prescribed Everolimus if you have advanced hormone receptor positive breast cancer."
Answered by AI
What is the success rate of AFINITOR?
"The average follow up duration was 23.7 months, 37 out of 53 patients were still alive at the end of the study, and the one and two year survival rates were 90.5% and 75.4% respectively. The median progression-free survival was 18.9 months."
Answered by AI
What are the side effects of AFINITOR?
"There is a chance you may experience the following side effects: Infections, Rash, Feeling weak or tired, Diarrhea, Swelling of arms, hands, feet, ankles, face, or other parts of the body, Stomach (abdominal) pain, Nausea, and Fever."
Answered by AI